

Manchester 2018 agenda

| Time | Session title | Session details |
|-------|---|---|
| 8.15 | Registration | |
| 9.15 | Welcome and introduction —Dr Matthew Fay | |
| 9.45 | Asthma—making a difference Dr Iain Small This session is sponsored by Chiesi  | <ul style="list-style-type: none"> BTS vs. NICE asthma guidelines |
| 10.30 | Personalised medicine in COPD Prof. Dave Singh This session is sponsored by Chiesi  | |
| 11.15 | Morning break | |
| 11.35 | Dermatology: Antibiotic resistance in dermatology Dr George Moncrieff This session is supported by Galderma  | <ul style="list-style-type: none"> Overview to antibiotic resistance in dermatology Introduction to relevant guidance Patient case study on how antibiotics should be used in the management of skin conditions Tips on implementing best practice  independent content |
| 12.20 | Liver: Improving outcomes by optimising, stratifying and managing patients with HE Dr Andrew Yeoman This session is sponsored by Norgine  | <ul style="list-style-type: none"> To demonstrate the benefits of early identification and appropriate management of these patients and the benefits to the NHS |
| 13.05 | Lunch | |
| 14.00 | Allergic rhinitis: New guidance Dr Dermot Ryan This session is supported by Mylan  | <ul style="list-style-type: none"> Introduction to the 2017 update of the BSACI rhinitis guideline: <ul style="list-style-type: none"> the rationale factors reviewed in the development of the guideline how the pathway aligns with current NICE guidance Key recommendations/changes for the updated guideline Implementing the guideline in practice—a case study  independent content |
| 14.45 | Dermatology: Best practice management of plaque psoriasis in primary care Dr George Moncrieff This session is sponsored by Leo  | <ul style="list-style-type: none"> Introduction to psoriasis Diagnosis of psoriasis Management of body and scalp plaque psoriasis in primary care Plaque psoriasis clinical case study Review of national guidelines |
| 15.30 | Tea break | |
| 15.50 | Diabetes: Current guidance in diabetes Dr Samuel Seidu This is an independent session | <ul style="list-style-type: none"> Introduction to the 2017 update of SIGN guideline 116 on the management of diabetes and SIGN guideline 154 on the pharmacological management of people with type 2 diabetes: <ul style="list-style-type: none"> the rationale factors that were considered how the pathway aligns with and/or differs from current NICE guidance Key recommendations/changes/differences between NICE and SIGN guidance Implementing the guidelines in practice—a case study  independent content |
| 16.50 | Summary and close —Dr Matthew Fay | |

Agenda correct at time of publication.

Please note that the programme is subject to change, and will be updated continuously up until the conference.

Sponsored presentations have been commissioned by pharmaceutical companies—the companies are responsible for the title and content of the presentation and the choice of speaker, and have paid the honorarium for the speaker. The companies have reviewed the content of the presentations to ensure they are fair and balanced and that they comply with appropriate regulations. The *Guidelines Live* team has not reviewed the content of these presentations.

Supported sessions have been funded by an educational grant from pharmaceutical companies; however, the companies have not had any involvement in the choice of speaker or the development of the presentation.

Independent sessions have been organised by MGP without financial support or involvement from any pharmaceutical companies.

The views and opinions of the speakers are not necessarily those of *Guidelines Live*, its advisers, or advertisers.